DO inhibitors target indoleamine 2,3-dioxygenase, an enzyme involved in immune regulation. By inhibiting IDO, these compounds can modulate immune responses, potentially enhancing the body's ability to fight cancer and other diseases. The study of IDO and its inhibitors is at the forefront of immunotherapy research, aiming to improve treatment options for various conditions.